338 related articles for article (PubMed ID: 21171079)
21. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
22. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
23. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
24. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone.
Balla P; Moskovszky L; Sapi Z; Forsyth R; Knowles H; Athanasou NA; Szendroi M; Kopper L; Rajnai H; Pinter F; Petak I; Benassi MS; Picci P; Conti A; Krenacs T
Histopathology; 2011 Sep; 59(3):376-89. PubMed ID: 22034878
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
28. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
[TBL] [Abstract][Full Text] [Related]
29. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
Sommer J; Itani DM; Homlar KC; Keedy VL; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Kelley MJ; Cates JM
J Pathol; 2010 Apr; 220(5):608-17. PubMed ID: 20140939
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor status in anaplastic thyroid carcinoma.
Lee DH; Lee GK; Kong SY; Kook MC; Yang SK; Park SY; Park SH; Keam B; Park DJ; Cho BY; Kim SW; Chung KW; Lee ES; Kim SW
J Clin Pathol; 2007 Aug; 60(8):881-4. PubMed ID: 17079354
[TBL] [Abstract][Full Text] [Related]
31. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma.
Kim JY; Lee J; Koh JS; Park MJ; Chang UK
J Neurosurg Spine; 2016 Nov; 25(5):626-635. PubMed ID: 27314550
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.
Shalaby AA; Presneau N; Idowu BD; Thompson L; Briggs TR; Tirabosco R; Diss TC; Flanagan AM
Mod Pathol; 2009 Aug; 22(8):996-1005. PubMed ID: 19407855
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
35. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Dewaele B; Floris G; Finalet-Ferreiro J; Fletcher CD; Coindre JM; Guillou L; Hogendoorn PC; Wozniak A; Vanspauwen V; Schöffski P; Marynen P; Vandenberghe P; Sciot R; Debiec-Rychter M
Cancer Res; 2010 Sep; 70(18):7304-14. PubMed ID: 20685895
[TBL] [Abstract][Full Text] [Related]
36. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
37. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours.
Higgins PA; Brady A; Dobbs SP; Salto-Tellez M; Maxwell P; McCluggage WG
Histopathology; 2014 Apr; 64(5):633-8. PubMed ID: 24206174
[TBL] [Abstract][Full Text] [Related]
39. Chordoma of the skull base: predictors of tumor recurrence.
Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
[TBL] [Abstract][Full Text] [Related]
40. Response to erlotinib in a patient with treatment refractory chordoma.
Singhal N; Kotasek D; Parnis FX
Anticancer Drugs; 2009 Nov; 20(10):953-5. PubMed ID: 19730087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
